This article describes the surveillance schemes that are routinely reported on in *Communicable Diseases Intelligence* (CDI).

Communicable disease surveillance in Australia operates at the national, state and local levels. Primary responsibility for public health action lies with the state and territory health departments. The role of communicable disease surveillance at a national level includes:

- detecting outbreaks and identifying national trends;
- guidance for policy development and resource allocation at a national level;
- monitoring the need for and impact of national disease control programs;
- coordination of response to national or multi-jurisdictional outbreaks;
- description of the epidemiology of rare diseases, that occur infrequently at state and territory levels;
- meeting various international reporting requirements, such as providing disease statistics to the World Health Organization; and
- support for quarantine activities, which are the responsibility of the national government.

State and territory health departments collect notifications of communicable diseases under their public health legislation. In September 2007, the *National Health Security Act 2007* (National Health Security Act, No 174) received royal assent. This Act provides a legislative basis for and authorises the exchange of health information, including personal information, between jurisdictions and the Commonwealth. The Act provides for the establishment of the *National Notifiable Diseases List* (NNDL), which specifies the diseases about which personal information can be provided. The *National Health Security Agreement*, which was drafted in 2007 and signed by Health Ministers in April 2008, establishes operational arrangements to formalise and enhance existing surveillance and reporting systems, an important objective of the Act. States and territories voluntarily forward de-identified data on a nationally agreed set of communicable diseases to the Department of Health and Ageing for the purposes of national communicable disease surveillance.

Surveillance has been defined by the World Health Organization as the ‘continuing scrutiny of all aspects of the occurrence and spread of disease that are pertinent to effective control.’ It is characterised by ‘methods distinguished by their practicability, uniformity, and frequently by their rapidity, rather than complete accuracy.’ Although some surveillance schemes aim for complete case ascertainment, others include only a proportion of all cases of the conditions under surveillance, and these samples are subject to systematic and other biases. Results generated from surveillance schemes must be interpreted with caution, particularly when comparing results between schemes, between different geographical areas or jurisdictions and over time. Surveillance data may also differ from data on communicable diseases gathered in other settings.

The major features of the surveillance schemes for which CDI publishes regular reports are described below:


**Australian Childhood Immunisation Register**

Accurate information on the immunisation status of children is needed at the community level for program management and targeted immunisation efforts. A population-based immunisation register can provide this need. The Australian Childhood Immunisation Register (ACIR) commenced operation on 1 January 1996 and is now an important component of the *Immunise Australia Program*. It is administered and operated by Medicare Australia. The Register was established by transferring data on all children under the age of 7 years enrolled with Medicare to the ACIR. This constitutes a nearly complete population register, as approximately 99% of children are registered with Medicare by 12 months of age. Children who are not enrolled in Medicare are added to the Register when a recognised immunisation provider supplies details of an eligible immunisation. Immunisations are generally notified to Medicare Australia either by electronic means, the Internet or by paper ACIR notification forms. Immunisations recorded on the Register must have been given in accordance with the guidelines for immunisation determined by the National Health and Medical Research Council.
From the data finally entered onto the ACIR, Medicare Australia provides regular quarterly coverage reports at the national and state level. Coverage for these reports is calculated using the cohort method described in Commun Dis Intell 1998;22:36–37. With this method, a cohort of children is defined by date of birth in 3-month groups. This birth cohort has the immunisation status of its members assessed at the 3 key milestones of 12 months, 24 months and 5 years of age. Analysis of coverage is undertaken 3 months after the due date for completion of each milestone, so that time is available for processing notifications and the impact on coverage estimates of delayed notification to the ACIR is minimised. Only children enrolled with Medicare are included in order to minimise inaccuracies in coverage estimates due to duplicate records.

Medicare Australia coverage reports for the 3 milestones are published in CDI each quarter. Coverage estimates are provided for each state and territory and Australia as a whole and for each individual vaccine assessed at each milestone. Changes in ‘fully immunised’ coverage from the previous quarter are also included in the tables.

A commentary on ACIR immunisation coverage estimates is included with the tables in each issue and graphs are used to provide trends in immunisation coverage.

An Immunisation Coverage Report is also published in CDI on an annual basis and provides more detailed data on immunisation coverage for all recommended vaccines by age group which are funded by the Immunise Australia Program, timeliness of immunisation, small area coverage estimates and data on conscientious objection to immunisation.

**Australian Gonococcal Surveillance Programme**

The Australian Gonococcal Surveillance Programme (AGSP) is a continuing program to monitor antimicrobial resistance in Neisseria gonorrhoeae and includes the reference laboratories in all states and territories. These laboratories report data on sensitivity to an agreed core group of antimicrobial agents on a quarterly basis and provide an expanded analysis as an annual report in CDI (Commun Dis Intell 2008;32:227–231). The antibiotics that are currently routinely surveyed are the penicillins, ceftriaxone, ciprofloxacin and spectinomycin, all of which are administered as single dose regimens. One main purpose of the AGSP is to help define standard protocols for antibiotic treatment of gonococcal infection. When in vitro resistance to a recommended agent is demonstrated in 5% or more of isolates, it is usual to reconsider the inclusion of that agent in current treatment schedules. Additional data are also provided on other antibiotics from time to time. At present all laboratories also test isolates for the presence of high level resistance to the tetracyclines and intermittent surveys of azithromycin resistance are conducted. Comparability of data is achieved by means of a standardised system of MIC testing and a program-specific quality assurance process.

**Australian Meningococcal Surveillance Programme**

The reference laboratories of the Australian Meningococcal Surveillance Programme report data of laboratory-confirmed cases confirmed either by culture or by non-culture techniques. Culture-positive cases where a Neisseria meningitidis is grown from a normally sterile site or skin, and non-culture based diagnoses, derived from results of nucleic acid amplification assays and serological techniques are defined as invasive meningococcal disease (IMD) according to Public Health Laboratory Network definitions.

Data are reported annually and quarterly in CDI. Data in the quarterly reports are restricted to a description of the number of cases per jurisdiction, and serogroup where known. A full analysis of laboratory-confirmed cases of IMD, including phenotyping and antibiotic susceptibility data are published annually (Commun Dis Intell 2009;33(1):1–9).

**Australian Paediatric Surveillance Unit**

The Australian Paediatric Surveillance Unit (APSU) is an active surveillance mechanism for prospective, national identification and study of children (< 15 years) with uncommon conditions of childhood, including rare infectious and vaccine preventable diseases, genetic disorders, child mental health problems, and rare injuries. Each month the APSU sends an e-mail or paper report card to approximately 1,360 paediatricians and other child health clinicians. Clinicians are asked to indicate whether or not they have seen a child newly diagnosed with any of the listed conditions listed. Clinicians reporting cases are asked to provide details about demographics, diagnosis, treatments and short-term outcomes. All negative and positive reports are logged into a database and the report card return rate has been maintained at over 90% over the last 19 years.

Communicable diseases currently under surveillance include: acute flaccid paralysis (to identify potential cases of poliovirus infection); congenital cytomegalovirus infection; congenital rubella; perinatal exposure to HIV and HIV infection, neonatal herpes simplex virus infection; neonatal
varicella, congenital varicella, severe complications of varicella, and juvenile onset recurrent respiratory papillomatosis.

After demonstrating feasibility in 2007, APSU continues to conduct surveillance for severe complications of influenza during the influenza season each year. In 2009 APSU contributed to the national surveillance effort during the Influenza H1N1 09 pandemic.

The activities of the APSU are funded in part by the Australian Government Department of Health and Ageing, NHMRC Practitioner Fellowship No: 1021480 (E Elliott). The Faculty of Medicine, The University of Sydney, and the Royal Australasian College of Physicians, Division of Paediatrics and Child Health, and the Kids Research Institute, Sydney Children’s Hospitals Network provide in-kind support.

For further information please contact the APSU Director, Professor Elizabeth Elliott on telephone: +61 2 9845 3005, facsimile +61 2 9845 3082 or email: apsu@chw.edu.au; Internet: www.apsu.org.au

Australian National Creutzfeldt-Jakob Disease Registry

The surveillance for CJD in Australia is conducted through the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). CJD has been scheduled as a notifiable disease in all Australian states and territories. The ANCJDR is under contract to the Commonwealth to identify and investigate all suspect cases of transmissible spongiform encephalopathies (TSE) in Australia. An annual update is published in CDI (Commun Dis Intell 2009;33(2):188–191).

Australian Sentinel Practice Research Network

The Royal Australian College of General Practitioners and the Department of General Practice at the University of Adelaide operate the Australian Sentinel Practices Research Network (ASPREN). ASPREN is a national network of general practitioners who report presentations of defined medical conditions each week. The main aims of ASPREN are to provide an indicator of the burden of disease in the primary health care setting and to act as an early warning indicator in the event of an influenza pandemic.

The list of conditions is reviewed annually by the ASPREN management committee and an annual report is published. In 2012, 4 conditions are being monitored; all of which are related to communicable diseases. These include influenza like illness, gastroenteritis, chickenpox and shingles.

Laboratory testing of ILI cases was implemented in 2010, allowing for viral testing of 25% of ILI patients for a range of respiratory viruses including influenza A, influenza B and H1N1(2009).

There are currently 170 general practitioners registered the network from all jurisdictions. Sixty-one per cent of these are in metropolitan areas, 29% in rural and 10% in remote areas of Australia. Approximately 9,000 consultations are recorded each week.

Data for communicable diseases are published in CDI every quarter. Data are presented in graphic format as the rate of reporting per 1,000 consultations per week. The conditions are defined as follows:

Influenza-like illness – record once only per patient

Must have the following: fever, cough and fatigue

Gastroenteritis – record once only per patient

Three or more loose stools, and/or 2 vomits in a 24 hour period excluding cases who have a known cause, for example bowel disease, alcohol, pregnancy.

Chickenpox – record once only per patient

An acute, generalised viral disease with a sudden onset of slight fever, mild constitutional symptoms and a skin eruption which is maculopapular for a few hours, vesicular for three to 4 days and leaves a granular scab.

Shingles – record once only per patient

Recurrence, recrudescence or re-activation of chickenpox infection. Vesicles with any erythematous base restricted to skin areas supplied by sensory nerves of a single or associated group of dorsal root ganglia. Lesions may appear in crops in irregular fashion along nerve pathways, are usually unilateral, deeper seated and more closely aggregated than those of chickenpox.

Note: Those conditions which show ‘record once only per patient’ are to have each occurrence of the condition only recorded on 1 occasion no matter how many patient contacts are made for this condition. If the condition occurs a second or subsequent time, it is to be recorded again. Conversely, for other conditions each attendance at which they are addressed in some way is to be recorded.
HIV and AIDS surveillance

National surveillance for HIV and AIDS is coordinated by the Kirby Institute in collaboration with state and territory health authorities, the Australian Government Department of Health and Ageing, the Australian Institute of Health and Welfare and other collaborating networks in surveillance for HIV, viral hepatitis and sexually transmissible infections.

Cases of HIV infection are notified to the National HIV Registry on the first occasion of diagnosis in Australia, either by the diagnosing laboratory (Australian Capital Territory and Tasmania), by doctor notification (Western Australia) or by a combination of laboratory and doctor sources (New South Wales, Northern Territory, Queensland, South Australia and Victoria). Cases of AIDS are notified through the state and territory health authorities to the National AIDS Registry. Diagnoses of both HIV infection and AIDS are notified with the person’s date of birth and name code, to minimise duplicate notifications while maintaining confidentiality.

Currently, 2 tables presenting the number of new diagnoses of HIV infection, AIDS and deaths following AIDS are published in each issue of CDI. The tabulations are based on data available 3 months after the end of the reporting period, to allow for reporting delay and to incorporate newly available information.

The document *viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report* has been published by the Kirby Institute from 1997. The Annual Surveillance Report, available through www.kirby.unsw.edu.au provides a comprehensive analysis and interpretation of surveillance data on HIV, viral hepatitis and sexually transmissible infections in Australia. The report *Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander people: Surveillance and Evaluation Report* has been published from 2007, as an accompanying document to the *Annual Surveillance Report*. The *Surveillance and Evaluation Report* provides detailed analysis and interpretation of the occurrence of these infections in Aboriginal and Torres Strait Islander communities in Australia.

National Influenza Surveillance Scheme

Australian influenza activity and severity in the community are monitored using a number of indicators and surveillance schemes:

- Notifications of laboratory-confirmed influenza are reported from all Australian states and territories and reported in the National Notifiable Diseases Surveillance System.

- Community level influenza-like illness (ILI) are monitored through two sentinel systems, Flutracking, a weekly online survey integrating syndromic information with participant influenza immunity status; and data from the National Health Call Centre Network.

- Reports on general practice ILI consultations are provided through the Australian Sentinel Practice Research Network and the Victorian Sentinel General Practice Scheme. Additionally, data on ILI presentations to hospital emergency departments are collected from sentinel hospitals sites in Western Australia and New South Wales.

- Hospitalised cases of laboratory-confirmed influenza are reported through the Influenza Complications Alert Network (FluCAN); and severe complications in children are monitored by the Australian Paediatric Surveillance Unit.

- Information on influenza subtypes and positivity are provided from sentinel laboratories, including the National Influenza Centre laboratories and some state public health laboratories. Additional virology and antiviral resistance data are also provided from the World Health Organization Collaborating Centre for Reference and Research on Influenza.

During the influenza season, data from each of these surveillance systems are compiled and published fortnightly in the Australian Influenza Report, which is available generally from May to October on the department’s web site. These reports include the above data as well as additional mortality and international surveillance data.

Annual reports on the National Influenza Surveillance Scheme are published in CDI each year (*Commun Dis Intell* 2010;34(1):8–22).

National Notifiable Diseases Surveillance System

National compilations of notifiable diseases have been published intermittently in a number of publications since 1917. The National Notifiable Diseases Surveillance System (NNDSS) was established in 1990 under the auspices of the Communicable Diseases Network Australia (CDNA).

Sixty-five communicable diseases agreed upon nationally are reported to NNDSS, although not all 65 are notifiable in each jurisdiction. Data are sent electronically from states and territories daily or several times a week. The system is complemented by other surveillance systems, which provide information on various diseases, including four that are not reported to NNDSS (AIDS, HIV, and the classical and variant forms of Creutzfeldt-Jakob disease).
The NNDSS core dataset includes data fields for a unique record reference number; notifying state or territory; disease code; age; sex; Indigenous status; postcode of residence; date of onset of the disease; death, date of report to the state or territory health department and outbreak reference (to identify cases linked to an outbreak). Where relevant, information on the species, serogroups/subtypes and phage types of organisms isolated, and on the vaccination status of the case is collected. Data quality is monitored by DoHA and the National Surveillance Committee (NSC) and there is a continual process of improving the national consistency of communicable disease surveillance.

While not included in the core national dataset, enhanced surveillance information for some diseases (hepatitis B [newly acquired], hepatitis C [newly acquired], invasive pneumococcal disease and tuberculosis) is obtained from states and territories.


Data are published in CDI every quarter and in an annual report. The reports include numbers of notifications for each disease by state and territory, and totals for Australia for the current period, the year to date, and for the corresponding period of the previous year. The national total for each disease is compared with the average number of notifications over the previous 5 years in the same period. A commentary on the notification data is included with the tables in each issue of CDI and graphs are used to illustrate important aspects of the data.

**OzFoodNet: enhanced foodborne disease surveillance**

The Australian Government Department of Health and Ageing established the OzFoodNet network in 2000 to collaborate nationally in the investigation of foodborne disease. OzFoodNet conducts studies on the burden of illness and coordinates national investigations into outbreaks of foodborne disease.

OzFoodNet reports quarterly on investigations of gastroenteritis outbreaks and clusters of disease potentially related to food. Annual reports have been produced and published in CDI (Commun Dis Intell 2009;33(4):389–413) since 2001. Data are reported from all Australian jurisdictions.

**Sentinel Chicken Surveillance Programme**

The Sentinel Chicken Surveillance Programme is used to provide an early warning of increased flavivirus activity in Australia. The main viruses of concern are Murray Valley encephalitis (MVEV) and Kunjin viruses. MVEV causes the disease Murray Valley encephalitis (formerly known as Australian encephalitis), a potentially fatal disease in humans. Encephalitis is less frequent in cases of Kunjin virus infection and these encephalitis cases have a lower rate of severe sequelae.

These viruses are enzootic in parts of the north-east Kimberley region of Western Australia and the Top End of the Northern Territory but are epizootic in other areas of the Kimberley, Pilbara, Gascoyne Murchison and Mid-west regions of Western Australia, in north Queensland and in Central Australia. MVEV is also responsible for occasional epidemics of encephalitis in eastern Australia. Since 1974, a number of sentinel chicken flocks have been established in Australia to provide an early warning of increased MVEV activity. These programs are supported by individual state health departments. Each state has a contingency plan that will be implemented if one or more chickens in a flock seroconverts to MVEV.

Currently, flocks are maintained in the north of Western Australia, the Northern Territory, New South Wales and in Victoria. The flocks in Western Australia and the Northern Territory are tested all year round but those in New South Wales and Victoria are tested only in the summer months, during the main MVEV risk season. Results are posted on the National Arbovirus and Malaria Advisory Committee web site. A yearly summary is presented in CDI (Commun Dis Intell 2012;36(1):70–81).

**References**